Canaccord Genuity Reiterates Hold on Thoratec (thor)

By admin | 7 years ago

Thoratec (NASDAQ: thor)‘s stock had its “hold” rating restated by equities researchers at Canaccord Genuity in a report issued on Wednesday.

Shares of Thoratec traded down 0.55% during mid-day trading on Wednesday, hitting $34.27. Thoratec has a 52 week low of $27.84 and a 52 week high of $38.07. The company has a market cap of $2.002 billion and a P/E ratio of 29.10.

The company last announced its quarterly results on Tuesday, May 1st. It reported $0.61 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $0.41 EPS by $0.20. The company’s quarterly revenue was up 27.4% on a year-over-year basis. On average, analysts predict that Thoratec will post $0.39 earnings per share next quarter.

Several other analysts have also recently commented on the stock. Analysts at Auriga reiterated a “hold” rating on shares of Thoratec in a research note to investors on Wednesday. Finally, analysts at Goldman Sachs (NYSE: GS) raised their price target on shares of Thoratec to $36.00 in a research note to investors on Friday, March 9th.

Thoratec Corporation is a manufacture of mechanical circulatory support (MCS) with a product portfolio to treat a range of clinical needs for advanced heart failure patients.

About the author